Eli Lilly and Company

143.14+0.3400+0.24%Vol 719.80K1Y Perf 31.76%
Oct 20th, 2020 12:17 DELAYED
BID143.11 ASK143.18
Open143.36 Previous Close142.80
Pre-Market143.50 After-Market143.50
 0.70 0.49%  0.70 0.49%
Target Price
174.71 
Analyst Rating
Moderate Buy 1.67
Potential %
22.00 
Finscreener Ranking
★★     45.94
Insiders Trans % 3/6/12 mo.
-100/-100/-45 
Value Ranking
★+     45.25
Insiders Value % 3/6/12 mo.
-100/-100/-84 
Growth Ranking
★★★★     61.43
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-79 
Income Ranking
★+     37.79
Market Cap136.91B 
Earnings Rating
Buy
Price Range Ratio 52W %
60.21 
Earnings Date
27th Oct 2020

Today's Price Range

142.11143.95

52W Range

101.36170.75

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-4.85%
1 Month
-7.37%
3 Months
-14.23%
6 Months
-9.50%
1 Year
31.76%
3 Years
63.71%
5 Years
86.02%
10 Years
383.12%

TickerPriceChg.Chg.%
LLY143.140.34000.24
AAPL117.341.36001.17
GOOG1 543.248.63000.56
MSFT215.261.04000.49
XOM33.560.14000.42
WFC22.840.30001.33
JNJ144.920.60000.42
FB265.984.58001.75
GE7.380.09001.23
JPM100.470.67000.67
Financial StrengthValueIndustryS&P 500US Markets
0.70
1.20
0.79
3.99
17.60
Leverage Ratio 13.20
ProfitabilityValueIndustryS&P 500US Markets
78.70
29.50
34.90
15.70
24.49
RevenueValueIndustryS&P 500US Markets
17.47B
18.27
-4.50
1.00
DividendsValueIndustryS&P 500US Markets
2.03
2.96
8.90
6.02
Payout ratio44.00
Earnings HistoryEstimateReportedSurprise %
Q02 20201.581.8919.62
Q01 20201.551.7512.90
Q04 20191.521.7313.82
Q03 20191.431.483.50
Q02 20191.461.502.74
Q01 20191.321.330.76
Q04 20181.361.33-2.21
Q03 20181.371.391.46
Earnings Per EndEstimateRevision %Trend
9/2020 QR1.791.13Positive
12/2020 QR1.888.05Positive
12/2020 FY7.296.89Positive
12/2021 FY7.991.14Positive
Next Report Date27th Oct 2020
Estimated EPS Next Report1.78
Estimates Count4
EPS Growth Next 5 Years %15.60
Volume Overview
Volume719.80K
Shares Outstanding956.47M
Trades Count12.53K
Dollar Volume113.01M
Avg. Volume3.87M
Avg. Weekly Volume2.65M
Avg. Monthly Volume3.47M
Avg. Quarterly Volume3.24M

Eli Lilly and Company (NYSE: LLY) stock closed at 142.8 per share at the end of the most recent trading day (a -2.27% change compared to the prior day closing price) with a volume of 3.16M shares and market capitalization of 136.91B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 38680 people. Eli Lilly and Company CEO is David A. Ricks.

The one-year performance of Eli Lilly and Company stock is 31.76%, while year-to-date (YTD) performance is 8.65%. LLY stock has a five-year performance of 86.02%. Its 52-week range is between 101.36 and 170.75, which gives LLY stock a 52-week price range ratio of 60.21%

Eli Lilly and Company currently has a PE ratio of 23.70, a price-to-book (PB) ratio of 34.15, a price-to-sale (PS) ratio of 8.00, a price to cashflow ratio of 21.00, a PEG ratio of 2.32, a ROA of 14.03%, a ROC of 29.93% and a ROE of 164.37%. The company’s profit margin is 24.49%, its EBITDA margin is 34.90%, and its revenue ttm is $17.47 Billion , which makes it $18.27 revenue per share.

Of the last four earnings reports from Eli Lilly and Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.78 for the next earnings report. Eli Lilly and Company’s next earnings report date is 27th Oct 2020.

The consensus rating of Wall Street analysts for Eli Lilly and Company is Moderate Buy (1.67), with a target price of $174.71, which is +22.00% compared to the current price. The earnings rating for Eli Lilly and Company stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eli Lilly and Company has a dividend yield of 2.03% with a dividend per share of $2.96 and a payout ratio of 44.00%.

Eli Lilly and Company has a Sell technical analysis rating based on Technical Indicators (ADX : 14.12, ATR14 : 3.68, CCI20 : -122.45, Chaikin Money Flow : -0.05, MACD : -0.87, Money Flow Index : 40.78, ROC : -1.66, RSI : 39.37, STOCH (14,3) : 3.95, STOCH RSI : 0.00, UO : 36.49, Williams %R : -96.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eli Lilly and Company in the last 12-months were: Aarti S. Shah (Sold 2 000 shares of value $300 000 ), Alfonso G. Zulueta (Option Excercise at a value of $0), Alfonso G. Zulueta (Sold 42 500 shares of value $6 680 000 ), Anne Nobles (Buy at a value of $108 840), Daniel Skovronsky (Buy at a value of $543 050), David A. Ricks (Buy at a value of $500 174), David A. Ricks (Option Excercise at a value of $0), Donald A. Zakrowski (Sold 3 700 shares of value $473 600 ), Jackson P. Tai (Buy at a value of $400 078), Johna L. Norton (Option Excercise at a value of $0), Johna L. Norton (Sold 4 727 shares of value $619 237 ), Joshua Smiley (Buy at a value of $99 951), Joshua Smiley (Option Excercise at a value of $0), Leigh Ann Pusey (Option Excercise at a value of $0), Melissa S. Barnes (Option Excercise at a value of $0), Melissa S. Barnes (Sold 5 000 shares of value $755 050 ), Michael Mason (Option Excercise at a value of $0), Myles O'Neill (Sold 50 000 shares of value $6 503 750 ), Stephen Fry (Option Excercise at a value of $0), Stephen Fry (Sold 21 861 shares of value $3 053 644 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (66.67 %)
6 (66.67 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (33.33 %)
3 (33.33 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.44

Eli Lilly and Company

Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.

CEO: David A. Ricks

Teplephone: +1 317 276-2000

Address: Lilly Corporate Center, Indianapolis 46285, IN, USA

Number of employees: 38 680

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

51%49%

Bearish Bullish

52%48%

News

Stocktwits